Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250910 | 0.86 | NPY2R (0.45) | MAPTLMNAALDH1A1NAMPTGPR119 | |
| SCHEMBL3251913 | 0.86 | MAPT (0.60) | MAPTLMNAALDH1A1NAMPTGPR119 | |
| SCHEMBL5539977 | 0.84 | MAPT (0.64) | MAPTLMNAALDH1A1NAMPTGPR119 | |
| SCHEMBL5573222 | 0.83 | MAPT (0.76) | MAPTLMNAALDH1A1NAMPTGPR119 | |
| SCHEMBL21965860 | 0.82 | MAPT (0.61) | MAPTLMNAALDH1A1NAMPTGPR119 | |
| SCHEMBL29080217 | 0.81 | MEN1 (0.54) | MAPTLMNAALDH1A1NAMPTGPR119 | |
| SCHEMBL31700443 | 0.81 | NAMPT (0.54) | MAPTNAMPTGPR119MEN1KMT2A | |
| SCHEMBL5231838 | 0.80 | MAPT (0.58) | MAPTLMNAALDH1A1NAMPTGPR119 | |
| SCHEMBL4940981 | 0.80 | MAPT (0.61) | MAPTLMNAALDH1A1NAMPTGPR119 | |
| SCHEMBL1459696 | 0.79 | MAPT (0.64) | MAPTLMNAALDH1A1NAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | MAPT 2494/4885LMNA 1912/4885ALDH1A1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.